NCT01583283 - Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2012

Primary Completion Date

March 15, 2021

Study Completion Date

March 24, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

ACY-1215

Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.

DRUG

lenalidomide

Dosed on Days 1-21 of a 28 day cycle.

DRUG

Dexamethasone

Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.

Trial Locations (5)

Massachusetts General Hospital, Boston

University of North Carolina, Chapel Hill

Sarah Cannon Research Institute Drug Development Unit, Nashville

Fred Hutchinson Cancer Research Center, Seattle

Dana Farber Cancer Institute, Boston